Annexin A5 in Patients With Severe COVID-19 Disease: A Single Centre, Randomized, Double-blind, Placebo-controlled Pilot Trial
Randomized, double-blind, placebo-controlled trial comparing 2 doses of SY-005 (recombinant human Annexin A5) to placebo in patients with severe coronavirus 2019 disease in a single hospital centre with 2 intensive care units
100 Clinical Results associated with Ontario Ministry of Colleges and Universities
0 Patents (Medical) associated with Ontario Ministry of Colleges and Universities
100 Deals associated with Ontario Ministry of Colleges and Universities
100 Translational Medicine associated with Ontario Ministry of Colleges and Universities